NCT05910801View on ClinicalTrials.gov

Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 4, 2024

Primary Completion Date

December 30, 2029

Study Completion Date

December 30, 2030

Conditions
Recurrent Mantle Cell LymphomaRefractory Mantle Cell Lymphoma
Interventions
PROCEDURE

Biopsy

Undergo biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy

PROCEDURE

Computed Tomography

Undergo CT scan

DRUG

Lenalidomide

Given PO

PROCEDURE

Lumbar Puncture

Undergo lumbar puncture

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Positron Emission Tomography

Undergo PET/CT scan

BIOLOGICAL

Tafasitamab

Given IV

DRUG

Venetoclax

Given PO

Trial Locations (2)

55905

RECRUITING

Mayo Clinic in Rochester, Rochester

77030

NOT_YET_RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Academic and Community Cancer Research United

OTHER